Falcon Investments invests in Ora Clinical, a leading Ophthalmology CRO
Junior Capital Supporting Vistria’s LBO
Falcon Investment Advisors ("Falcon") is pleased to announce an investment in Ora LLC (“Ora”, "Ora Clinical", or the “Company”), a fullservice ophthalmology-focused Contract Research Organization. Falcon led a junior capital investment in support of an acquisition by The Vistria Group, LP ("Vistria").
Ora is one of the world’s leading full-service ophthalmic drug and device development firms, offering pre-clinical, clinical, consulting and regulatory, and patient and site solutions. The Company supports a wide array of organizations, from start-ups to global pharmaceutical and device companies, to efficiently bring their new products from concept to market.
"Falcon is pleased to partner with Vistria and Ora on this next phase of the Company’s growth. Ora’s reputation as a leader in the ophthalmic clinic research space is supported by an exceptional track record and a highly tenured team. We look forward to supporting Vistria and Ora’s expansion efforts on their exciting journey ahead," said Jonathan Moses, a Managing Director at Falcon
Forward-Looking Statements
This press release may contain, without limitation, statements concerning possible or assumed future operations, performance or results preceded by, followed by or that include words such as “believes”, “expects”, “potential”, “anticipates”, “estimates”, “intends”, “plans” and words of similar connotation, which would constitute forward-looking statements. Forward-looking statements are not guarantees. The reader should not place undue reliance on forward-looking statements and information because they involve significant and diverse risks and uncertainties that may cause actual operations, performance or results to be materially different from those indicated in these forward-looking statements. Except as may be required by applicable securities law, Falcon is under no obligation to update any forward-looking statements contained herein should material facts change due to new information, future events or other factors. These cautionary statements expressly qualify all forward-looking statements in this press release.